Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer
Clinical trial NCT03122717 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03122717
- Sponsor
- Dana-Farber Cancer Institute
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-05-09
- Primary completion
- 2026-10-01
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.